Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile Virus infection

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11007-11021

  Thackray, Larissa B ^a   Shrestha, Bimmi ^a   Richner, Justin M ^a   Miner, Jonathan J ^a   Pinto, Amelia K ^a   Lazear, Helen M ^a   Gale, Michael ^b   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERFERON; INTERFERON REGULATORY FACTOR 5; DOCK2 PROTEIN, MOUSE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, MOUSE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INNATE IMMUNITY; LYMPH NODE; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PLASMA CELL; PROTEIN DEPLETION; VIRUS INACTIVATION; VIRUS TRANSMISSION; WEST NILE FEVER; WEST NILE FLAVIVIRUS; ADAPTIVE IMMUNITY; ANIMAL; B LYMPHOCYTE; BLOOD; CROSS BREEDING; FEMALE; GENE DELETION; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MALE; MUTATION; PATHOLOGY; TRANSGENIC MOUSE; VIROLOGY; VIRUS LOAD;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; CROSSES, GENETIC; FEMALE; GENE DELETION; GENE EXPRESSION; GTPASE-ACTIVATING PROTEINS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTORS; LYMPH NODES; MALE; MICE; MICE, TRANSGENIC; MUTATION; VIRAL LOAD; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84906982919     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01545-14     Document Type: Article

References (59)

1. Honda K, Taniguchi T. 2006. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658. http://dx.doi.org/10.1038/nri1900.
2. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferonmediated signaling. Nat. Rev. Immunol. 5:375-386. http://dx.doi.org/10 .1038/nri1604.
3. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1:519-525. http://dx.doi .org/10.1016/j.coviro.2011.10.008.
4. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777. http://dx.doi.org/10.1038/nature03464.
5. Daffis S, Suthar MS, Szretter KJ, Gale M, Jr., Diamond MS. 2009. Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog. 5:e1000607. http://dx.doi.org/10.1371/journal.ppat .1000607.
6. Steinberg C, Eisenacher K, Gross O, Reindl W, Schmitz F, Ruland J, Krug A. 2009. The IFN regulatory factor 7-dependent type I IFN response is not essential for early resistance against murine cytomegalovirus infection. Eur. J. Immunol. 39:1007-1018. http://dx.doi.org/10.1002/eji.200838814.
7. Chen HW, King K, Tu J, Sanchez M, Luster AD, Shresta S. 2013. The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus. J. Immunol. 191:4194-4201. http://dx.doi.org/10.4049/jimmunol .1300799.
8. Thackray LB, Duan E, Lazear HM, Kambal A, Schreiber RD, Diamond MS, Virgin HW. 2012. Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication. J. Virol. 86:13515-13523. http://dx.doi.org/10.1128/JVI .01824-12.
9. Schilte C, Buckwalter MR, Laird ME, Diamond MS, Schwartz O, Albert ML. 2012. Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to Chikungunya infection. J. Immunol. 188:2967-2971. http://dx.doi.org/10.4049 /jimmunol.1103185.
10. Daffis S, Lazear HM, Liu WJ, Audsley M, Engle M, Khromykh AA, Diamond MS. 2011. The naturally attenuated Kunjin strain of West Nile virus shows enhanced sensitivity to the host type I interferon response. J. Virol. 85:5664-5668. http://dx.doi.org/10.1128/JVI.00232-11.
11. Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, Anraku I, Kumagai Y, Loo YM, Gale M, Jr., Akira S, Khromykh AA, Suhrbier A. 2012. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J. Virol. 86:9888-9898. http://dx.doi .org/10.1128/JVI.00956-12.
12. Suthar MS, Ma DY, Thomas S, Lund JM, Zhang N, Daffis S, Rudensky AY, Bevan MJ, Clark EA, Murali-Krishna KJ, Diamond MS, Gale M. 2010. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog. 6:e1000757. http://dx.doi.org/10.1371/journal .ppat.1000757.
13. You F, Wang P, Yang L, Yang G, Zhao YO, Qian F, Walker W, Sutton R, Montgomery R, Lin R, Iwasaki A, Fikrig E. 2013. ELF4 is critical for induction of type I interferon and the host antiviral response. Nat. Immunol. 14:1237-1246. http://dx.doi.org/10.1038/ni.2756.
14. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, Clepper L, Thackray L, Brassil MM, Virgin HW, Nikolich-Zugich J, Moses AV, Gale M, Jr., Fruh K, Diamond MS. 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog. 9:e1003118. http://dx .doi.org/10.1371/journal.ppat.1003118.
15. Barnes BJ, Kellum MJ, Field AE, Pitha PM. 2002. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol. 22:5721-5740. http://dx.doi.org/10.1128/MCB.22.16.5721-5740.2002.
16. Barnes BJ, Moore PA, Pitha PM. 2001. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 276:23382-23390. http://dx .doi.org/10.1074/jbc.M101216200.
17. Barnes BJ, Field AE, Pitha-Rowe PM. 2003. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J. Biol. Chem. 278:16630-16641. http://dx.doi.org/10.1074/jbc.M212609200.
18. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T. 2005. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243-249. http://dx.doi.org/10.1038/nature03308.
19. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT. 2005. The interferon regulatory factor, IRF5, is a central mediator of Toll-like receptor 7 signaling. J. Biol. Chem. 280:17005-17012. http://dx.doi.org/10.1074/jbc.M412584200.
20. Paun A, Reinert JT, Jiang Z, Medin C, Balkhi MY, Fitzgerald KA, Pitha PM. 2008. Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J. Biol. Chem. 283:14295-14308. http://dx.doi.org/10.1074/jbc.M800501200.
21. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A, Honda K, Taniguchi T. 2007. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl. Acad. Sci. U. S. A. 104:3402-3407. http://dx.doi.org/10.1073/pnas.0611559104.
22. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. 2004. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J. Biol. Chem. 279:45194-45207. http://dx.doi.org/10 .1074/jbc.M400726200.
23. Purtha WE, Swiecki M, Colonna M, Diamond MS, Bhattacharya D. 2012. Spontaneous mutation of the Dock2 gene in Irf5_/_ mice complicates interpretation of type I interferon production and antibody responses. Proc. Natl. Acad. Sci. U. S. A. 109:E898-E904. http://dx.doi.org /10.1073/pnas.1118155109.
24. Yasuda K, Nundel K, Watkins AA, Dhawan T, Bonegio RG, Ubellacker JM, Marshak-Rothstein A, Rifkin IR. 2013. Phenotype and function of B cells and dendritic cells from interferon regulatory factor 5-deficient mice with and without a mutation in DOCK2. Int. Immunol. 25:295-306. http: //dx.doi.org/10.1093/intimm/dxs114.
25. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe M, Inayoshi A, Noda M, Oike M, Shirai T, Sasazuki T. 2001. Haematopoietic cellspecific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412:826-831. http://dx.doi.org/10.1038/35090591.
26. Gotoh K, Tanaka Y, Nishikimi A, Inayoshi A, Enjoji M, Takayanagi R, Sasazuki T, Fukui Y. 2008. Differential requirement for DOCK2 in migration of plasmacytoid dendritic cells versus myeloid dendritic cells. Blood 111:2973-2976. http://dx.doi.org/10.1182/blood-2007-09-112169.
27. Gotoh K, Tanaka Y, Nishikimi A, Nakamura R, Yamada H, Maeda N, Ishikawa T, Hoshino K, Uruno T, Cao Q, Higashi S, Kawaguchi Y, Enjoji M, Takayanagi R, Kaisho T, Yoshikai Y, Fukui Y. 2010. Selective control of type I IFN induction by the Rac activator DOCK2 during TLRmediated plasmacytoid dendritic cell activation. J. Exp. Med. 207:721- 730. http://dx.doi.org/10.1084/jem.20091776.
28. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586. http://dx .doi.org/10.1128/JVI.77.4.2578-2586.2003.
29. Fang CM, Roy S, Nielsen E, Paul M, Maul R, Paun A, Koentgen F, Raval FM, Szomolanyi-Tsuda E, Pitha PM. 2012. Unique contribution of IRF- 5-Ikaros axis to the B-cell IgG2a response. Genes Immun. 13:421-430. http://dx.doi.org/10.1038/gene.2012.10.
30. Pinto AK, Richner JM, Poore EA, Patil PP, Amanna IJ, Slifka MK, Diamond MS. 2013. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J. Virol. 87:1926-1936. http://dx.doi.org/10.1128 /JVI.02903-12.
31. Mehlhop E, Diamond MS. 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203:1371-1381. http://dx.doi.org/10.1084/jem.20052388.
32. Diamond MS, Sitati E, Friend L, Shrestha B, Higgs S, Engle M. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862. http://dx.doi.org/10.1084/jem .20031223.
33. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. 2011. Memory B cells but not long-lived plasma cells possess antigen specificities for viral escape mutants J. Exp. Med. 208:2599-2606. http://dx.doi .org/10.1084/jem.20110740.
34. Purtha WE, Myers N, Mitaksov V, Sitati E, Connolly J, Fremont DH, Hansen TH, Diamond MS. 2007. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur. J. Immunol. 37:1845-1854. http://dx.doi.org/10.1002/eji.200737192.
35. Jin YH, Kim SJ, So EY, Meng L, Colonna M, Kim BS. 2012. Melanoma differentiation-associated gene 5 is critical for protection against Theiler's virus-induced demyelinating disease. J. Virol. 86:1531-1543. http://dx.doi .org/10.1128/JVI.06457-11.
36. Daffis S, Samuel MA, Suthar MS, Gale M, Jr., Diamond MS. 2008. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 82:10349-10358. http://dx.doi.org/10.1128/JVI.00935-08.
37. Szretter KJ, Daffis S, Patel J, Suthar MS, Klein RS, Gale M, Jr., Diamond MS. 2010. The innate immune adaptor molecule MyD88 restricts West Nile replication and spread in neurons of the central nervous system. J. Virol. 84:12125-12138. http://dx.doi.org/10.1128/JVI.01026-10.
38. Purtha WE, Chachu KA, Virgin HW, Diamond MS. 2008. Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J. Virol. 82:10964-10974. http://dx.doi .org/10.1128/JVI.01646-08.
39. Sitati E, Diamond MS. 2006. CD4+ T Cell responses are required for clearance of West Nile Virus from the central nervous system. J. Virol. 80:12060-12069. http://dx.doi.org/10.1128/JVI.01650-06.
40. Shrestha B, Diamond MS. 2004. The role of CD8+ T cells in the control of West Nile virus infection. J. Virol. 78:8312-8321. http://dx.doi.org/10 .1128/JVI.78.15.8312-8321.2004.
41. Brien JD, Uhrlaub JL, Hirsch A, Wiley CA, Nikolich-Zugich J. 2009. Key role of T cell defects in age-related vulnerability to West Nile virus. J. Exp. Med. 206:2735-2745. http://dx.doi.org/10.1084/jem.20090222.
42. Brien JD, Uhrlaub JL, Nikolich-Zugich J. 2007. Protective capacity and epitope specificity of CD8+ T cells responding to lethal West Nile virus infection. Eur. J. Immunol. 37:1855-1863. http://dx.doi.org/10.1002/eji .200737196.
43. Lien C, Fang CM, Huso D, Livak F, Lu R, Pitha PM. 2010. Critical role of IRF-5 in regulation of B-cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 107:4664-4668. http://dx.doi.org/10.1073/pnas.0911193107.
44. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K. 2010. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc. Natl. Acad. Sci. U. S. A. 107:10154-10159. http://dx.doi.org/10.1073/pnas.1005599107.
45. Chambers TJ, Droll DA, Walton AH, Schwartz J, Wold WS, Nickells J. 2008. West Nile 25A virus infection of B-cell-deficient ((micro)MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein. J. Gen. Virol. 89:627-635. http://dx.doi.org/10.1099/vir .0.83297-0.
46. Shrestha B, Wang T, Samuel MA, Whitby K, Craft J, Fikrig E, Diamond MS. 2006. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80:5338-5348. http://dx .doi.org/10.1128/JVI.00274-06.
47. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, Rifkin IR. 2007. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 178:6876-6885. http://dx.doi.org/10.4049/jimmunol.178.11.6876.
48. Richez C, Yasuda K, Watkins AA, Akira S, Lafyatis R, van Seventer JM, Rifkin IR. 2009. TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming. J. Immunol. 182:820-828. http://dx.doi.org/10.4049/jimmunol.182.2.820.
49. Dai P, Cao H, Merghoub T, Avogadri F, Wang W, Parikh T, Fang CM, Pitha PM, Fitzgerald KA, Rahman MM, McFadden G, Hu X, Houghton AN, Shuman S, Deng L. 2011. Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway. J. Virol. 85:10814-10825. http://dx.doi.org/10.1128/JVI.00104-11.
50. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. U. S. A. 103:8459-8464. http: //dx.doi.org/10.1073/pnas.0603082103.
51. Ouyang X, Negishi H, Takeda R, Fujita Y, Taniguchi T, Honda K. 2007. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. Biochem. Biophys. Res. Commun. 354:1045-1051. http://dx .doi.org/10.1016/j.bbrc.2007.01.090.
52. Nandakumar R, Finsterbusch K, Lipps C, Neumann B, Grashoff M, Nair S, Hochnadel I, Lienenklaus S, Wappler I, Steinmann E, Hauser H, Pietschmann T, Kroger A. 2013. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms. Gastroenterology 145:1414-1423 e1411. http://dx.doi.org/10.1053/j.gastro .2013.08.037.
53. Li S, Wang L, Berman M, Kong YY, Dorf ME. 2011. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 35:426-440. http://dx.doi.org/10.1016/j.immuni .2011.06.014.
54. Negishi H, Yanai H, Nakajima A, Koshiba R, Atarashi K, Matsuda A, Matsuki K, Miki S, Doi T, Aderem A, Nishio J, Smale ST, Honda K, Taniguchi T. 2012. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat. Immunol. 13:659-666. http://dx.doi.org/10.1038/ni.2307.
55. Feng D, Sangster-Guity N, Stone R, Korczeniewska J, Mancl ME, Fitzgerald-Bocarsly P, Barnes BJ. 2010. Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J. Immunol. 185:6003-6012. http://dx.doi.org /10.4049/jimmunol.1000482.
56. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, Jonsen A, Rantapaa-Dahlqvist S, Moller B, Kere J, Koskenmies S, Widen E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Ronnblom L, Syvanen AC. 2005. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76:528-537. http: //dx.doi.org/10.1086/428480.
57. Feng D, Stone RC, Eloranta ML, Sangster-Guity N, Nordmark G, Sigurdsson S, Wang C, Alm G, Syvanen AC, Ronnblom L, Barnes BJ. 2010. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum. 62:562-573.
58. Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ. 2011. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 13:R111. http://dx.doi.org/10.1186/bcr3053.
59. Yamashita M, Toyota M, Suzuki H, Nojima M, Yamamoto E, Kamimae S, Watanabe Y, Kai M, Akashi H, Maruyama R, Sasaki Y, Yamano H, Sugai T, Shinomura Y, Imai K, Tokino T, Itoh F. 2010. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer Sci. 101:1708-1716. http://dx.doi.org/10.1111/j.1349-7006.2010.01581.x.